Tohoku Univ. Technology：Treatment and Diagnosis of Cancer or Infectious Disease using Recognition Mechanism of TCR：T16-051
TCR-IgFc work as an NK cell function enhancer
While NK cells have been expected to be used in the treatment of cancer and infectious diseases, their limitations in medical applications have been pointed out because they can not recognize cancer cells or infected cells having MHC class I molecules expressed therein. The present invention is about the use of chimeric proteins comprising a variable region of a T-cell receptor and an Fc region of an immunoglobulin, which can make NK cells easily recognize target cells. It was found that by using the chimeric proteins of the present invention, in addition to the previously reported T-cell receptor chimeric protein-dependent cellular cytotoxicity (TDCC) activity, down-modulation of MHC complexes on the target cells: the expression of MHC class I molecules can be reduced and converted into the target of NK cells' intrinsic cytotoxic activity (see the right figure). The combination of T-cell receptor repertoire analysis (see WO 2016/136716) enables rapid chimeric protein development and the design of NK cell-based therapies tailored to individual cancers, viral infections, autoimmune diseases, allergies and other clinical manifestations.
Inquire About This Product
basic information
For details, please contact us or refer to the PDF.
Price range
Delivery Time
Applications/Examples of results
For details, please contact us or refer to the PDF.
catalog（1）
Download All Catalogs
Company information
The revenue generated from technology transfer is reinvested into universities and researchers as new research funding, which is used to create further research outcomes. To ensure the smooth operation of this cycle, known as the "Intellectual Creation Cycle," we will actively promote technology transfer. The types of seeds we handle include patents, know-how, databases, and programs. We have established a collaborative framework by concluding basic technology transfer agreements with the following universities (as of April 1, 2026): - Tohoku University - Hirosaki University - Iwate University - Akita University - Fukushima University - Yamagata University - Tohoku Gakuin University - Iwate Medical University - Fukushima Medical University - Aizu University - Miyagi University - Hokkaido University - Muroran Institute of Technology - Showa Medical University - Asahikawa Medical University
